Clinical Trials · NCT06005012

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Name: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 2Semaglutide

Phase: Phase 2
Recruitment status: Active Not Recruiting
Sponsor: University of California, San Diego
Enrollment: 120
Start date: Jul 2023
Locations: 1 site, United States
Primary endpoint: Change in fibrosis due to NAFLD

View Semaglutide compound reference